Literature DB >> 23860494

BRAF test and cytological diagnosis with a single fine needle cytology sample.

Giuseppe Di Benedetto1, Alessio Fabozzi, Carmine Rinaldi, Ciro Roberto Rinaldi.   

Abstract

OBJECTIVE: Recently, fine needle cytology (FNC) of the thyroid has been combined with biomolecular analysis. In particular, there has been detailed study of the V600E-BRAF mutation. The aim of our study is to demonstrate that with a single thyroid sample it is possible to obtain enough cellular material for both cytological diagnosis and a V600E-BRAF molecular test. STUDY
DESIGN: FNC was carried out under ultrasound guidance aided by an echographist and cytopathologist. We acquired one biopsy for each nodule with a 23-gauge needle without suction. The preparations were smeared by the pathologist onto one glass slide, air dried and stained with Diff-Quick. Cell adequacy was evaluated for each patient. The needle was washed by aspirating 2 ml of physiologic solution which was collected into a tube. The material was collected for molecular testing.
RESULTS: The following cytological diagnoses were made: not neoplastic, Tir2 (n = 227); indeterminate, Tir3 (n = 15); suspicious, Tir4 (n = 4), and malignancy, Tir5 (n = 12). The V600E-BRAF mutation was found in 0 of 227 Tir2 specimens, 2 of 15 (13.3%) Tir3 specimens, 2 of 4 (50%) Tir4 specimens and 9 of 12 (75%) Tir5 specimens.
CONCLUSIONS: Our data showed that, in a routine clinical setting, FNC specimens can be handled properly to provide both morphological and molecular information. In fact, our tests show that with a single specimen it is possible to set up a slide for the cytological diagnosis and to obtain enough residual cellular material for DNA extraction (>70 ng) and for the identification of the V600E-BRAF mutation.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860494     DOI: 10.1159/000350618

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  7 in total

1.  High-Resolution Melting Is a Sensitive, Cost-Effective, Time-Saving Technique for BRAF V600E Detection in Thyroid FNAB Washing Liquid: A Prospective Cohort Study.

Authors:  Marco Marino; Maria Laura Monzani; Giulia Brigante; Katia Cioni; Bruno Madeo; Daniele Santi; Antonino Maiorana; Stefania Bettelli; Valeria Moriondo; Elisa Pignatti; Lara Bonacini; Cesare Carani; Vincenzo Rochira; Manuela Simoni
Journal:  Eur Thyroid J       Date:  2015-05-30

2.  Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.

Authors:  Jae Young Seo; Eun-Kyung Kim; Jin Young Kwak
Journal:  Endocrine       Date:  2014-01-23       Impact factor: 3.633

3.  Thyroid fine-needle aspiration: the relevance of BRAF mutation testing.

Authors:  Giuseppe Di Benedetto
Journal:  Endocrine       Date:  2014-03-04       Impact factor: 3.633

4.  The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma.

Authors:  Zi-Mei Lin; Cao-Xin Yan; Yue Song; Yu-Rong Hong; Qing Wen; Yong-Yuan Xu; Min-Qiang Pan; Qin Ye; Pin-Tong Huang
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

5.  BRAF mutation may predict higher necessity of postoperative radioactive iodine ablation in papillary thyroid cancer.

Authors:  Sang-Ah Han; Won Seo Park; Jae-Hoon Jang; Sun-Young Min; Jung Kyu Ryu; Jeong-Yoon Song
Journal:  Ann Surg Treat Res       Date:  2014-09-25       Impact factor: 1.859

6.  Diagnostic value of BRAF (V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis.

Authors:  Xingyun Su; Xiaoxia Jiang; Xin Xu; Weibin Wang; Xiaodong Teng; Anwen Shao; Lisong Teng
Journal:  Onco Targets Ther       Date:  2016-04-27       Impact factor: 4.147

7.  Nomogram based on radiomics analysis of ultrasound images can improve preoperative BRAF mutation diagnosis for papillary thyroid microcarcinoma.

Authors:  Jiajia Tang; Shitao Jiang; Jiaojiao Ma; Xuehua Xi; Huilin Li; Liangkai Wang; Bo Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.